Editas Medicine (EDIT) Receivables (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Receivables of $15.2 million for Q4 2025, down 6.7% year-over-year from $16.3 million in Q4 2024, and up 86.67% quarter-over-quarter from $8.1 million in Q3 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Receivables (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Receivables for 11 consecutive years, with $15.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables fell 6.7% year-over-year to $15.2 million; the TTM figure through Dec 2025 stood at $15.2 million (down 6.7% YoY), while the FY2025 annual figure was $15.2 million, down 6.7% from the prior year.
- Receivables improved to $15.2 million in Q4 2025 per EDIT's latest filing, from $8.1 million in the prior quarter.
- Across five years, Receivables topped out at $16.3 million in Q4 2024 and bottomed at $120000.0 in Q3 2022.
- Historically, Receivables has averaged $3.3 million across 5 years, with a median of $630000.0 in 2021.
- Annual changes were most pronounced in 2021 — Receivables sank 95.59% — and 2025, when it surged 6352.38%.
- Editas Medicine's Receivables stood at $267000.0 in 2021, then jumped by 1826.97% to $5.1 million in 2022, then surged by 98.0% to $10.2 million in 2023, then soared by 59.67% to $16.3 million in 2024, then fell by 6.7% to $15.2 million in 2025.
- Business Quant data shows EDIT's Receivables at $15.2 million in Q4 2025, $8.1 million in Q3 2025, and $588000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | 15.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 15.18 Mn |
| Sep 30, 2025 | 8.13 Mn |
| Jun 30, 2025 | 588,000.00 |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | 16.27 Mn |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 244,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 10.19 Mn |
| Sep 30, 2023 | 2.42 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 242,000.00 |
| Dec 31, 2022 | 5.15 Mn |
| Sep 30, 2022 | 120,000.00 |
| Jun 30, 2022 | 713,000.00 |
| Mar 31, 2022 | 1.37 Mn |
| Dec 31, 2021 | 267,000.00 |
| Sep 30, 2021 | 251,000.00 |
| Jun 30, 2021 | 331,000.00 |
| Mar 31, 2021 | 672,000.00 |